ASK1-P38 pathway is important for anoikis induced by microtubule- targeting aryl chloroethylureas

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 2, 2010, Pages 175-190

  Fortin, Jessica ^a,b,c   Patenaude, Alexandre ^a,d   Deschesnes, Réna G ^a   Côté, Marie France ^a   Petitclerc, Eric ^a,b   C Gaudreault, René ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF ARIZONA   (United States)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 CHLOROETHYL)UREA DERIVATIVE; ANTIMITOTIC AGENT; APOPTOSIS SIGNAL REGULATING KINASE 1; CEU 022; CEU 025; CEU 098; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PAXILLIN; PROTEIN BCL 2; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; THIOREDOXIN; UNCLASSIFIED DRUG;

ANOIKIS; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MICROTUBULE; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 78650364895     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j31g6c     Document Type: Article

References (44)

1. Fan M, Goodwin M, Vu T, Brantley-Finley C, Gaarde WA and Chambers TC. Vinblastineinduced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem, 2000; 275(39):29980-29985.
2. Hadfield JA, Ducki S, Hirst N and McGown AT. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res, 2003; 5:309-325.
3. Mani S, Macapinlac M, Jr., Goel S, Verdier-Pinard D, Fojo T, Rothenberg M and Colevas D. The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs, 2004; 15(6):553-558.
4. Moreau E, Fortin S, Desjardins M, Rousseau JL, Petitclerc E and C.- Gaudreault R. Optimized Nphenyl- N'-(2-chloroethyl)ureas as potential antineoplastic agents: Synthesis and growth inhibition activity. Bioorg Med Chem, 2005; 13(24):6703-6712.
5. Prinz H. Recent advances in the field of tubulin polymerization inhibitors. Expert Rev Anticancer Ther, 2002; 2(6):695-708.
6. Fan M, Du L, Stone A.A, Gilbert K.M and Chambers T.C. Modulation of mitogen-activated protein kinases and phosphorylation of Bcl-2 by vinblastine represent persistent forms of normal luctuations at G2-M1. Cancer Res, 2000; 60(22):6403-6407.
7. Srivastava RK, Mi QS, Hardwick JM and Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci U S A, 1999; 96(7):3775-3780.
8. Yamamoto K, Ichijo H and Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol, 1999; 19(12):8469-8478.
9. Ito T, Deng X, Carr B and May WS. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem, 1997; 272(18):11671-11673.
10. Johnson GL and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 2002; 298(5600):1911-1912.
11. Dent P, Yacoub A, Fisher PB, Hagan MP and Grant S. MAPK pathways in radiation responses. Oncogene, 2003; 22(37):5885-5896.
12. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta, 2007; 1773(8):1263-1284.
13. Turjanski AG, Vaque JP and Gutkind JS. MAP kinases and the control of nuclear events. Oncogene, 2007; 26(22):3240-3253.
14. Marone M, D'Andrilli G, Das N, Ferlini C, Chatterjee S and Scambia G. Quercetin abrogates taxol-mediated signaling by inhibiting multiple kinases. Exp Cell Res, 2001; 270(1):1-12.
15. Wang TH, Popp DM, Wang HS, Saitoh M, Mural JG, Henley DC, Ichijo H and Wimalasena J. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem, 1999; 274(12):8208-8216.
16. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. Embo J, 1998; 17(9):2596-2606.
17. Legault J, Gaulin JF, Mounetou E, Bolduc S, Lacroix J, Poyet P and C.-Gaudreault R. Microtubule disruption induced in vivo by alkylation of beta-tubulin by 1-aryl-3-(2- chloroethyl)ureas, a novel class of soft alkylating agents. Cancer Res, 2000; 60(4):985-992.
18. Petitclerc E, Deschesnes RG, Cote MF, Marquis C, Janvier R, Lacroix J, Miot-Noirault E, Legault J, Mounetou E, Madelmont JC and C.- Gaudreault R. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance. Cancer Res, 2004; 64(13):4654-4663.
19. Patenaude A, Deschesnes RG, Rousseau JL, Petitclerc E, Lacroix J, Cote MF and R CG. New Soft Alkylating Agents with Enhanced Cytotoxicity against Cancer Cells Resistant to Chemotherapeutics and Hypoxia. Cancer Res, 2007; 67(5):2306-2316.
20. Fortin S, Wei L, Moreau E, Labrie P, Petitclerc E, Kotra LP, C-Gaudreault R. Mechanism of action of N-phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between alpha- and beta-tubulin. J Med Chem, 2009; 17(10):3690-7.
21. Fortin JS, Lacroix J, Desjardins M, Patenaude A, Petitclerc E and R CG. Alkylation potency and protein specificity of aromatic urea derivatives and bioisosteres as potential irreversible antagonists of the colchicine-binding site. Bioorg Med Chem, 2007; 15(13):4456-4469.
22. Bouchon B, Chambon C, Mounetou E, Papon J, Miot-Noirault E, Gaudreault RC, Madelmont JC and Degoul F. Alkylation of beta-tubulin on Glu 198 by a microtubule disrupter. Mol Pharmacol, 2005; 68(5):1415-1422.
23. Deschesnes RG, Patenaude A, Rousseau JL, Fortin JS, Ricard C, Cote MF, Huot J, R CG and Petitclerc E. Microtubule-destabilizing agents induce focal adhesion structure disorganization and anoikis in cancer cells. J Pharmacol Exp Ther, 2007; 320(2):853-864.
24. Bouchon B, Papon J, Communal Y, MadelmontJC and Degoul F. Alkylation of prohibitin by cyclohexylphenyl-chloroethyl urea on an aspartyl residue is associated with cell cycle G(1) arrest in B16 cells. Br J Pharmacol, 2007; 152(4):449-455.
25. Fortin JS, Cote MF, Lacroix J, Desjardins M, Petitclerc E and R CG. Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents. Bioorg Med Chem, 2008; 16(15):7277-90.
26. Fortin JS, Cote MF, Lacroix J, Patenaude A, Petitclerc E and R CG. Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation. Bioorg Med Chem Lett, 2008; 18(12):3526-3531.
27. Fortin JS, Cote MF, Lacroix J, Petitclerc E and R CG. Aromatic 2-chloroethyl urea derivatives and bioisosteres. Part 2: Cytocidal activity and effects on the nuclear translocation of thioredoxin-1, and the cell cycle progression. Bioorg Med Chem, 2008; 16(15):7277-90.
28. Dhillon AS, Hagan S, Rath O and Kolch W. MAP kinase signalling pathways in cancer. Oncogene, 2007; 26(22):3279-3290.
29. Masanek U, Stammler G and Volm M. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin. Anticancer Drugs, 1997; 8(2):189-198.
30. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Science, 2007; 98(5):629-635.
31. Mizumura K, Takeda K, Hashimoto S, Horie T and Ichijo H. Identification of Op18/stathmin as a potential target of ASK1-p38 MAP kinase cascade. J Cell Physiol, 2006; 206(2):363-370.
32. Andersen SS. Spindle assembly and the art of regulating microtubule dynamics by MAPs and Stathmin/Op18. Trends Cell Biol, 2000; 10(7):261-267.
33. Grossmann J, Artinger M, Grasso AW, Kung HJ, Scholmerich J, Fiocchi C and Levine AD. Hierarchical cleavage of focal adhesion kinase by caspases alters signal transduction during apoptosis of intestinal epithelial cells. Gastroenterology, 2001; 120(1):79-88.
34. Grossmann J. Molecular mechanisms of detachment-induced apoptosis--Anoikis. Apoptosis, 2002; 7(3):247-260.
35. Schmidmaier R, Mandl-Weber S, Gaul L, Baumann P, Bumeder I, Straka C and Emmerich B. Inhibition of lymphocyte function associated antigen 1 by LFA878 induces apoptosis in multiple myeloma cells and is associated with downregulation of the focal adhesion kinase/phosphatidylinositol 3 kinase/Akt pathway. Int J Oncol, 2007; 31(4):969-976.
36. Hatai T, Matsuzawa A, Inoshita S, Mochida Y, Kuroda T, Sakamaki K, Kuida K, Yonehara S, Ichijo H and Takeda K. Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria-dependent caspase activation. J Biol Chem, 2000; 275(34):26576-26581.
37. Wen LP, Fahrni JA, Troie S, Guan JL, Orth K and Rosen GD. Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem, 1997; 272(41):26056-26061.
38. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, Minowa O, Miyazono K, Noda T, Ichijo H. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO rep, 2001; 2(3):222-228.
39. Lillig CH and Holmgren A. Thioredoxin and related molecules from biology to health and disease. Antioxid Redox Signal, 2007; 9(1):25-47.
40. Luduena RF and Roach MC. Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents. Pharmacol Ther, 1991; 49(1-2):133-152.
41. Shan B, Medina JC, Santha E, Frankmoelle WP, Chou TC, Learned RM, Narbut MR, Stott D, Wu P, Jaen JC, Rosen T, Timmermans PB and Beckmann H. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci U S A, 1999; 96(10):5686-5691.
42. Khan IA and Luduena RF. Possible regulation of the in vitro assembly of bovine brain tubulin by the bovine thioredoxin system. Biochim Biophys Acta, 1991; 1076(2):289-297.
43. Landino LM, Skreslet TE and Alston JA. Cysteine oxidation of tau and microtubule-associated protein-2 by peroxynitrite: modulation of microtubule assembly kinetics by the thioredoxin reductase system. J Biol Chem, 2004; 279(33):35101-35105.
44. Chalmers CJ, Gilley R, March HN, Balmanno K, Cook SJ. The duration of ERK1/2 activity determines the activation of c-Fos and Fra-1 and the composition and quatitative transcriptional output of AP-1. Cellular Signalling, 2007; 19:695-704.